MIRAMAR BEACH, Fla.--(BUSINESS WIRE)--Rainbow Coral Corp. (RBCC) is taking full advantage of more research-friendly regulations north of the border to target new personalized medicine opportunities in Canada. These opportunities include marketing cutting-edge treatments utilizing adult stem cells and the reprogramming of a patient’s own existing cells to combat a variety of diseases, such as multiple sclerosis, ALS (Lou Gehrig’s disease) and Parkinson’s.
“The Canadian regulatory environment is much more conducive to our continued and future business success,” said RBCC CEO Kimberly Palmer. “Canada has become a major player in the commercialization of biotechnology and nanomedicine. As a pioneer in regenerative medicine, it’s a natural fit for us to be here. Canada has welcomed and encouraged RBCC, providing us a place to research and innovate game-changing personal medicine technologies that will truly revolutionize the way diseases and health problems are treated.”
Because of its strong support of stem cell research, Canada has become one of the world’s top three countries in stem cell patents and commercialization. The country is encouraging and attracting new initiatives and investments with regulations that promote development.
“Thanks to this regulation-friendly environment, we expect strong opportunities that will benefit patients and profit our investors,” Palmer said. “Working in Canada will enable us to make innovations in implantable stem cell technologies and cell reprogramming that will fully restore the health of damaged tissue.”
RBCC is dedicated to delivering advanced medical research and technologies to a booming global health marketplace, predicted to be worth $224 billion by 2017. For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
